このページの翻訳は実験的なもので、現在開発中です。お待ちしております

CXI Healthcare Technology Group 将来の成長

Future 基準チェック /06

現在、 CXI Healthcare Technology Groupの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Personal Products 収益成長	13.8%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Aug 05

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

May 30

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 02

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、CXI Healthcare Technology Group は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

KOSDAQ:A900120 - アナリストの将来予測と過去の財務データ ( )KRW Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2024	67,194	21,013	42,610	42,610	N/A
12/31/2023	68,673	17,446	41,272	41,272	N/A
9/30/2023	69,715	12,117	35,049	35,049	N/A
6/30/2023	71,617	7,528	31,597	31,597	N/A
3/31/2023	79,065	1,294	33,115	33,121	N/A
12/31/2022	87,718	3,198	34,513	34,519	N/A
9/30/2022	98,052	9,532	37,885	37,891	N/A
6/30/2022	101,376	5,981	35,979	35,984	N/A
3/31/2022	103,312	6,182	31,884	34,802	N/A
12/31/2021	105,354	4,302	-78,688	33,577	N/A
9/30/2021	108,284	2,762	-131,371	24,526	N/A
6/30/2021	104,593	5,098	-196,165	8,723	N/A
3/31/2021	81,035	-55,823	-279,044	-11,374	N/A
12/31/2020	64,812	-70,201	-182,182	-23,860	N/A
9/30/2020	63,264	-83,142	-152,506	-37,816	N/A
6/30/2020	63,406	-98,437	-110,022	-44,322	N/A
3/31/2020	82,358	-61,945	-41,425	-41,418	N/A
12/31/2019	106,374	-64,559	-51,724	-51,707	N/A
9/30/2019	117,046	-67,216	-50,748	-50,706	N/A
6/30/2019	129,309	-70,621	-58,101	-58,060	N/A
3/31/2019	147,921	-64,977	-64,012	-63,977	N/A
12/31/2018	149,568	-66,308	-60,023	-59,997	N/A
9/30/2018	148,347	-72,578	-64,361	-64,361	N/A
6/30/2018	145,264	-73,933	-57,435	-57,435	N/A
3/31/2018	120,456	-70,977	-34,535	-34,471	N/A
12/31/2017	120,228	-49,884	N/A	-13,879	N/A
9/30/2017	125,336	-24,445	N/A	14,958	N/A
6/30/2017	146,319	786	N/A	54,284	N/A
3/31/2017	190,109	18,964	N/A	48,143	N/A
12/31/2016	228,969	29,945	N/A	65,841	N/A
9/30/2016	269,185	42,624	N/A	75,067	N/A
6/30/2016	297,600	52,396	N/A	59,172	N/A
3/31/2016	311,164	60,931	N/A	88,396	N/A
12/31/2015	318,262	66,823	N/A	86,723	N/A
9/30/2015	321,330	71,473	N/A	89,229	N/A
6/30/2015	317,895	73,452	N/A	95,513	N/A
3/31/2015	312,412	69,309	N/A	77,966	N/A
12/31/2014	303,794	68,530	N/A	74,266	N/A
9/30/2014	291,664	65,401	N/A	75,546	N/A
6/30/2014	286,376	63,604	N/A	77,930	N/A
3/31/2014	285,469	66,365	N/A	87,930	N/A
12/31/2013	279,352	62,672	N/A	83,793	N/A
9/30/2013	273,763	62,077	N/A	67,534	N/A

アナリストによる今後の成長予測

収入対貯蓄率: A900120の予測収益成長が貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: A900120の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: A900120の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: A900120の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: A900120の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: A900120の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

CXI Healthcare Technology Group 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

Investor sentiment improves as stock rises 28%

New major risk - Shareholder dilution

First quarter 2024 earnings released: EPS: ₩34.00 (vs ₩16.00 in 1Q 2023)

CKH Food & Health Limited announced that it has received KRW 7.432995165 billion in funding

New minor risk - Share price stability

Investor sentiment improves as stock rises 35%

Investor sentiment deteriorates as stock falls 16%

New major risk - Shareholder dilution

Third quarter 2023 earnings released: ₩6.00 loss per share (vs ₩7.00 profit in 3Q 2022)

Second quarter 2023 earnings released: ₩41.00 loss per share (vs ₩2.00 loss in 2Q 2022)

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.

First quarter 2023 earnings released: EPS: ₩16.00 (vs ₩11.00 loss in 1Q 2022)

No independent directors

Investor sentiment improved over the past week

CKH Food & Health Limited announced that it has received KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited

CKH Food & Health Limited announced that it expects to receive KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited, and other investors

Third quarter 2022 earnings released: EPS: ₩7.00 (vs ₩9.00 loss in 3Q 2021)

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99981 million.

Third quarter 2021 earnings released: ₩9.00 loss per share (vs ₩139 loss in 3Q 2020)

CKH Food & Health Limited announced that it has received KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it expects to receive KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it has received KRW 679.08 million in funding

CKH Food & Health Limited announced that it expects to receive KRW 679.08 million in funding

Second quarter 2021 earnings released: ₩17.00 loss per share (vs ₩133 loss in 2Q 2020)

New 90-day low: ₩405

First quarter 2021 earnings released: EPS ₩10.00

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: ₩354

New 90-day high: ₩295

New 90-day high: ₩274

New 90-day low - ₩212

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘